Genetesis Announces Two Abstracts Selected for Presentations at Upcoming Scientific Meetings

×

Error message

  • Notice: Undefined property: stdClass::$ds_changed in eval() (line 16 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$ss_search_api_url in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$tm_title in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$ds_changed in eval() (line 16 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$ss_search_api_url in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$tm_title in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).

Genetesis, a market leading biomagnetic imaging company, has announced that recent data collected in clinical study with the companys lead product, CardioFlux was selected for abstract presentations at this years American College of Emergency Physicians (ACEP) Scientific Assembly later this month and at American Heart Association (AHA) Scientific Sessions in November.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Tuesday, October 19, 2021
Information
Tags: 
Hardware, Other Education, Technology, Continuing, Education, Training, General Health, Medical Devices, Clinical Trials, Cardiology, Science, Software, Other Science, Health, Research, DO, Attending physician, Magnetocardiography, American College of Emergency Physicians, Diagnosis, Use, Dipyridamole, Therapy, FDA, Google Images, Cardiovascular disease, American Heart Association, Moyamoya disease, Ascension Michigan, American College, Ascension St. Mary's Hospital, ACEP, AHA, Coronary artery disease, Trial of the century, Medical imaging
Geotags: 
Ohio, United States, MASON
⚠generated by AI ↴
Summary
Key Points: 
  • Genetesis, a market leading biomagnetic imaging company, has announced that recent data collected in clinical study with the companys lead product, CardioFlux was selected for abstract presentations at this years American College of Emergency Physicians (ACEP) Scientific Assembly later this month and at American Heart Association (AHA) Scientific Sessions in November.
  • These presentations will discuss the utility and improvements to standard of care when using CardioFlux as a diagnostic imaging solution to detect myocardial ischemia and diagnose coronary artery disease.
  • The CardioFlux Magnetocardiograph has been designated a FDA Breakthrough Device for its potential benefits in improving and optimizing care in the triage process.
  • Genetesis was founded in 2013 and is based in Mason, Ohio.


Genetesis, a market leading biomagnetic imaging company, has announced that recent data collected in clinical study with the company’s lead product, CardioFlux was selected for abstract presentations at this year’s American College of Emergency Physicians (ACEP) Scientific Assembly later this month and at American Heart Association (AHA) Scientific Sessions in November. These presentations will discuss the utility and improvements to standard of care when using CardioFlux as a diagnostic imaging solution to detect myocardial ischemia and diagnose coronary artery disease. The CardioFlux Magnetocardiograph has been designated a FDA Breakthrough Device for its potential benefits in improving and optimizing care in the triage process.

American College of Emergency Physicians (ACEP) Research Forum:

Title: Detection of Acute Coronary Syndrome by Magnetocardiography

Date and Time: Tuesday, October 26, 2021 at 11:00 a.m. ET

Session Name: RF 18 Abstract Session: Cardiovascular (ACS and non-ACS)

Session Type: Oral Abstract Session

Presenter: Sharon Mace, MD, FACEP, FAAP, Principal Investigator of ACCMED, Emergency Medicine Physician at Cleveland Clinic

Abstract #: 1145

American Heart Association (AHA) Scientific Sessions:

Title: A Novel Way to Predict Obstructive Coronary Artery Disease Requiring Revascularization: The Use of Magnetocardiography

Date: Saturday, November 13 – Monday, November 15, 2021

Session Name: Health Tech Posters II

Session Type: Abstract Poster Presentation

Presenter: Nicholas Coriasso, DO, Cardiology Fellow (PGY5) at Ascension St. John Hospital

Abstract #: 10642

About Genetesis

Genetesis, Inc. is a medical imaging company focused on redefining the way myocardial ischemia and coronary artery disease are detected. By combining CardioFlux, our noninvasive biomagnetic imaging technology, with our proprietary cloud-based web services and machine-learning capabilities, we seek to become the standard of care for diagnosis of cardiovascular disease in the outpatient and acute care settings. Genetesis was founded in 2013 and is based in Mason, Ohio. For more information, visit https://genetesis.com/.

Copyright: 
Copyright Business Wire 2021